Time & Date: 4 September, 12:45 – 13:45 CEST
Chairpersons: F. Behar-Cohen SWITZERLAND & G. Cheung SINGAPORE
Speakers & Presentations:
F. Behar-Cohen SWITZERLAND
12:45 Welcome
J.I. Fernandez-Vigo SPAIN
12:47 Deep learning to assess the prediction of response to photodynamic therapy in patients with chronic central serous chorioretinopathy based on optical coherence tomography images.
J.I. Fernandez-Vigo SPAIN
12:53 Short-term impact of verteporfin shortage in the treatment of central serous chorioretinopathy
E. Van Dijk THE NETHERLANDS
12:59 Spontaneous resolution of subretinal fluid in chronic central serous chorioretinopathy: the Fuji sign
R. Mirshahi IRAN
13:05 Differentiating pachychoroid from healthy choroid: an unsupervised machine learning approach
H. Feenstra THE NETHERLANDS
13:11 Safety and efficacy of fovea-involving half-dose photodynamic therapy for chronic central serous chorioretinopathy
F. Behar-Cohen SWITZERLAND
13:17 Pentraxin-3 and lipocalin 2, encoded by two corticoid-induced genes, are decreased in the serum of patients with central serous chorioretinopathy
S. Emil Künzel GERMANY
12:23 Transcriptome analysis of the human choroid and RPE qualifies endothelial androgen responses as a disease driver for Central Serous Chorioretinopathy
L. Keidel GERMANY
13:29 Pachysclera as a risk factor for central serous chorioretinopathy and pachychoroid neovascularisation
L. Pauleikhoff GERMANY
13:35 Presentation and first results of the German registry for Central Serous Chorioretinopathy
All Faculty
13:41 Discussion
